Zithromax Powder for Oral Suspension 200 mg/5 ml

  • Name:

    Zithromax Powder for Oral Suspension 200 mg/5 ml

  • Company:
    info
  • Active Ingredients:

    Azithromycin dihydrate

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 05/04/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 29/5/2019

Click on this link to Download PDF directly

Pfizer Healthcare Ireland

Pfizer Healthcare Ireland

Company Products

Medicine NameActive Ingredients
Medicine Name Trazimera - 150mg & 420mg powder for solution for infusion Active Ingredients Trastuzumab
Medicine Name Trosyl 283mg/ml Nail Solution Active Ingredients Tioconazole
Medicine Name TRUMENBA Active Ingredients Meningococcal group B vaccine (recombinant, adsorbed)
Medicine Name Tygacil 50mg powder for solution for infusion Active Ingredients Tigecycline
Medicine Name VFEND 200 mg powder and solvent for solution for infusion Active Ingredients Voriconazole
Medicine Name VFEND 200 mg powder for solution for infusion Active Ingredients Voriconazole
Medicine Name VFEND 40mg/ml powder for oral suspension Active Ingredients Voriconazole
Medicine Name VFend 50mg and 200mg film-coated tablets Active Ingredients Voriconazole
Medicine Name Viagra 25MG, 50MG, 100MG Active Ingredients sildenafil citrate
Medicine Name Vibramycin Capsules 100mg Active Ingredients Doxycycline hyclate
Medicine Name Vinblastine Sulfate 1 mg/ml Solution for Injection or Infusion Active Ingredients Vinblastine sulfate
Medicine Name Vincristine Sulphate 1 mg/ml Solution for Injection or Infusion Active Ingredients Vincristine sulphate
Medicine Name Vizimpro 15, 30 & 45 mg film-coated tablets Active Ingredients dacomitinib monohydrate
Medicine Name Xalacom eye drops, solution Active Ingredients Latanoprost, Timolol Maleate
Medicine Name Xalatan 50 micrograms/ml eye drops solution Active Ingredients Latanoprost
Medicine Name Xalkori 200mg and 250 mg hard capsules Active Ingredients Crizotinib
Medicine Name Xanax 1 mg Tablets Active Ingredients Alprazolam
Medicine Name Xanax 500 microgram Tablets Active Ingredients Alprazolam
Medicine Name Xanax Tablets 250 micrograms Active Ingredients Alprazolam
Medicine Name Xeljanz 10mg film coated tablets Active Ingredients Tofacitinib citrate
Medicine Name Xeljanz 5mg film coated tablets Active Ingredients Tofacitinib citrate
Medicine Name Zavedos 5mg Powder for Solution for Injection Active Ingredients Idarubicin Hydrochloride
Medicine Name Zavicefta 2g/0.5g powder for concentrate for solution for infusion Active Ingredients Ceftazidime Pentahydrate, Avibactam sodium
Medicine Name Zinforo 600 mg powder for concentrate for solution for infusion Active Ingredients Ceftaroline Fosamil
Medicine Name ZITHROMAX CAPSULES 250MG Active Ingredients Azithromycin dihydrate
201 - 225 of 231 items.Total: 10 pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 29 May 2019 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 5 April 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - date of revision

Updated on 5 April 2019 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 4.8 DRESS frequency has been corrected from Very Rare to Rare

Updated on 30 October 2018 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 8 - Marketing authorisation number(s)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:
Section 7 has been updated from Current MAH Pfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK to Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Subsequently section 8 has also been updated with the HPRA newly appointed Marketing Authorisation number.

Updated on 25 October 2018 PIL

Reasons for updating

  • Change to section 6 - marketing authorisation holder
  • Change to section 6 - marketing authorisation number
  • Change to section 6 - date of revision

Updated on 23 July 2018 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

4.6. Fertility, pregnancy and lactation

Subsection on breast-feeding updated in line with CDS.

Updated on 15 May 2018 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 14 May 2018 SmPC

Reasons for updating

  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

4.5. Interactions with other medicinal products and other forms of interaction

Inclusion of colchicine

Updated on 8 May 2018 PIL

Reasons for updating

  • Change to section 2 - interactions with other medicines, food or drink

Updated on 17 July 2017 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 17 July 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows: Section 4.4 has been updated in line with the CDS

Updated on 14 July 2017 PIL

Reasons for updating

  • New PIL for new product

Updated on 14 July 2017 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 6 - date of revision

Updated on 21 April 2017 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 4.4 of the SmPC has been updated to include the addition of text regarding the increased incidence of infantile hypertrophic pyloric stenosis (IHPS) in neonates in connection with the use of Azithromycin.

Updated on 20 April 2017 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 6 - date of revision

Updated on 8 March 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 4.4 of the SmPC has been updated to include the addition of text regarding the increased incidence of infantile hypertrophic pyloric stenosis (IHPS) in neonates in connection with the use of Azithromycin.

Updated on 7 March 2016 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to date of revision

Updated on 14 January 2016 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

The SPC has been updated as follows:

Section 4.8 of the SmPC has been updated to add the Adverse Drug Reaction ‘DRESS’ and consequentially the Section 4.4 of the SmPC has been updated to revise the text on hypersensitivity reactions.

Updated on 12 January 2016 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to warnings or special precautions for use
  • Change to storage instructions
  • Change to side-effects
  • Change to drug interactions
  • Change to further information section
  • Change to date of revision
  • Change to dosage and administration

Updated on 16 December 2014 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 5.1 - Pharmacodynamic properties

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

·         Section 4.2 of the SmPC has been updated to add text relating to use in the elderly.

·         Section 4.4 of the SmPC has been updated to revise the text on hypersensitivity, hepatotoxicity. In     addition an enhanced precautionary text on prolongation of the QT interval has been added.

·         Section 4.5 of the SmPC has been updated to add precautionary text for Digoxin and to add text for

·         Atorvastin.

·         Section 4.6 ofthe SmPC has been updated to add text pertaining to breast milk and fertility.

·         Section 4.8 of the SmPC has been updated to add the Adverse Drug Reactions 'deafness', 'tinnitus'   and 'hearing impaired' to the Post-marketing subsection.

·         Section 5.1 of the SmPC now includes updated text on microbiology information.

·         Section 4.4 of the SmPC has been updated to draw attention to the possible fatal issue of QT prolongation

·         Section 5.1 of the SmPC now includes updated text on cardiac electrophysiology with regards to co-administration of azithromycin and chloroquine.

To align with CSP

Updated on 9 December 2014 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to drug interactions
  • Change to information about pregnancy or lactation
  • Change to further information section
  • Change to date of revision

Updated on 25 June 2014 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

update section 4.1 and 4.2 of the SmPC include the indication gonococcal infection treatment and relevant dosing included in section 4.2

Updated on 20 June 2014 PIL

Reasons for updating

  • Change to, or new use for medicine
  • Change to date of revision
  • Change to dosage and administration

Updated on 2 April 2013 SmPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 31 July 2012 PIL

Reasons for updating

  • Change to information about pregnancy or lactation
  • Change to date of revision
  • Change to dosage and administration

Updated on 22 July 2011 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change of contraindications
  • Change to side-effects
  • Change to drug interactions
  • Change to date of revision

Updated on 5 February 2010 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 3 November 2008 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects

Updated on 27 September 2007 PIL

Reasons for updating

  • Change of special precautions for disposal

Updated on 30 July 2007 PIL

Reasons for updating

  • Change of trade or active ingredient name
  • Change to storage instructions
  • Change to date of revision
  • Change from the BAN of the active substance to the rINN

Updated on 26 October 2006 PIL

Reasons for updating

  • Change to warnings or special precautions for use
  • Change to side-effects
  • Change to further information section

Updated on 30 September 2004 PIL

Reasons for updating

  • New PIL for medicines.ie